- Home
- GORV vs TNXP Comparison
GORV vs TNXP Comparison
Compare GORV & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- TNXP
- Stock Information
- Founded
- GORV 1976
- TNXP 2007
- Country
- GORV United States
- TNXP United States
- Employees
- GORV N/A
- TNXP N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- TNXP Health Care
- Exchange
- GORV Nasdaq
- TNXP Nasdaq
- Market Cap
- GORV 52.1M
- TNXP 57.9M
- IPO Year
- GORV 2015
- TNXP N/A
- Fundamental
- Price
- GORV $0.80
- TNXP $0.24
- Analyst Decision
- GORV Hold
- TNXP Strong Buy
- Analyst Count
- GORV 2
- TNXP 2
- Target Price
- GORV $2.00
- TNXP $53.50
- AVG Volume (30 Days)
- GORV 67.0K
- TNXP 134.8M
- Earning Date
- GORV 03-07-2025
- TNXP 11-12-2024
- Dividend Yield
- GORV N/A
- TNXP N/A
- EPS Growth
- GORV N/A
- TNXP N/A
- EPS
- GORV N/A
- TNXP N/A
- Revenue
- GORV $920,774,000.00
- TNXP $11,291,000.00
- Revenue This Year
- GORV N/A
- TNXP $64.71
- Revenue Next Year
- GORV $6.13
- TNXP $24.49
- P/E Ratio
- GORV N/A
- TNXP N/A
- Revenue Growth
- GORV N/A
- TNXP 183.05
- 52 Week Low
- GORV $0.75
- TNXP $0.12
- 52 Week High
- GORV $5.30
- TNXP $12.48
- Technical
- Relative Strength Index (RSI)
- GORV 41.89
- TNXP 43.95
- Support Level
- GORV $0.75
- TNXP $0.22
- Resistance Level
- GORV $0.98
- TNXP $0.26
- Average True Range (ATR)
- GORV 0.08
- TNXP 0.04
- MACD
- GORV -0.00
- TNXP -0.02
- Stochastic Oscillator
- GORV 17.56
- TNXP 7.38
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.